Iovance Biotherapeutics is trading at $8.06, up 4.13%, as biotech and major U.S. indexes rise. - Third-quarter results reported November 5 showed revenue of $121.5 million, beating estimates; management reaffirmed full-year revenue guidance of $410–$420 million. - Shares fell 11.03% on November 5 despite the results, with available reporting linking the decline partly to broader market weakness.